What is the purpose of this study?
This phase I trial studies the side effects and
best dose of AR-42 when given together with decitabine in treating patients
with acute myeloid leukemia. AR-42 may stop the growth of cancer cells by
blocking some of the enzymes needed for cell growth. Drugs used in
chemotherapy, such as decitabine, work in different ways to stop the growth of
cancer cells, either by killing the cells or by stopping them from dividing.
Giving AR-42 together with decitabine may kill more cancer cells.